Discovery and development of gliflozins: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
<languages /> | |||
<translate> | |||
[[Gliflozin]]s are a class of drugs in the treatment of [[type 2 diabetes]] (T2D). They act by inhibiting [[sodium/glucose cotransporter 2]] (SGLT-2), and are therefore also called SGLT-2 inhibitors. The efficacy of the drug is dependent on renal excretion and prevents [[glucose]] from going into blood circulation by promoting [[glucosuria]]. The mechanism of action is insulin independent. | [[Gliflozin]]s are a class of drugs in the treatment of [[type 2 diabetes]] (T2D). They act by inhibiting [[sodium/glucose cotransporter 2]] (SGLT-2), and are therefore also called SGLT-2 inhibitors. The efficacy of the drug is dependent on renal excretion and prevents [[glucose]] from going into blood circulation by promoting [[glucosuria]]. The mechanism of action is insulin independent. | ||
| Line 129: | Line 131: | ||
[[Category:Drug discovery|Gliflozins]] | [[Category:Drug discovery|Gliflozins]] | ||
[[Category:SGLT2 inhibitors| ]] | [[Category:SGLT2 inhibitors| ]] | ||
</translate> | |||